2013 - CTS 2013 Congress

This page contains exclusive content for the member of the following sections: TTS, CTS. Log in to view.

Oral Communications 10

21.5 - Autologous transplantation of bone marrow mononuclear cells in patients with decompensated cirrhosis. Phase I clinical trial

Presenter: Ekaterine, Berishvili, Tbilisi, Georgia
Authors: Ekaterine Berishvili1,2,3,4,5, Zurab Kakabadze1,2,3,4,5, Gocha Shatirishvili1,2,3,4,5, George Loladze1,2,3,4,5, Konstantin Mardaleishvili1,2,3,4,5, Nicolas Kipshidze1,2,3,4,5, Akaki Archvadze1,2,3,4,5

Autologous transplantation of bone marrow mononuclear cells in patients with decompensated cirrhosis. Phase I clinical trial

Ekaterine Berishvili1,2,3,4,5, Zurab Kakabadze1,2,3,4,5, Gocha Shatirishvili1,2,3,4,5, George Loladze1,2,3,4,5, Konstantin Mardaleishvili1,2,3,4,5, Nicolas Kipshidze1,2,3,4,5, Akaki Archvadze1,2,3,4,5

1Tbilisi State Medical University, Tbilisi, Georgia; 2Central University Hospital, Tbilisi, Georgia; 3Georgian National Institute of Medical Research, Tbilisi, Georgia; 4Mardaleishvili Medical Center, Tbilisi, Georgia; 5Ilia State University, Tbilisi, Georgia

 

Background:Liver cirrhosis is characterized by distortion of the hepatic architecture and the formation of regenerative nodules. Liver transplantation is one of the few available therapies for such patients. It has been shown recently, that hat bone marrow cell infusion repairs liver fibrosis in the cirrhotic liver.
Methods:This study was performed to determine the safety and tolerability of intrahepatic transplantation of autologous bone marrow mononuclear cells into five patients with liver insufficiency. The bone marrow mononuclear cells were isolated and infused into liver via hepatic artery. At different time points after the transplantation, the liver function and prothrombin time (PT) were evaluated, and the survival rate and symptoms of the patients were recorded.
Results:No complications or specific side effects related to the procedure were observed; all patients showed improvements in serum albumin, bilirubin and ALT after one month from the cell infusion. Conclusion: Our study has shown both the safety and feasibility of this type of liver cell therapy and may be a bridge to liver transplantation
 

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada

Info

Privacy Policy
Terms of Use
Copyright Notice